FDA Approves Tremfya (guselkumab) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

FDA News, New FDA Approvals
February 27, 2019
A+ A-
Email Print

Article Link: FDA Approves Tremfya (guselkumab) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

HORSHAM, PENNSYLVANIA, February 27, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya One-Press, a single-dose, patient-controlled injector for…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post